A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

Sponsor
Novo Nordisk A/S
Study ID
NCT04083820
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.

Study Details

The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.

Key Dates

Start date
Sep 16, 2019
Status verified
Mar 2023
Primary completion
Sep 27, 2021
Completion
Sep 27, 2021

Study Design

Enrollment
521 participants (actual)

Arms

  • Arm: Semaglutide s.c. once-weekly
    Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.

Primary Outcome Measure

Change in Glycated Haemoglobin A1c (HbA1c) [ Time Frame: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38) ]

Related Studies